Author: admin

DelveInsight’s, “Dementia Associated With Alzheimer’s Disease Pipeline Insight 2025” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Dementia Associated With Alzheimer’s Disease pipeline landscape. It covers the Dementia Associated With Alzheimer’s Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Dementia Associated With Alzheimer’s Disease therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Dementia Associated With Alzheimer’s Disease Research. Learn more about our innovative pipeline today! @ Dementia Associated With Alzheimer’s Disease Pipeline Outlook

Key Takeaways from the Dementia Associated With Alzheimer’s Disease Pipeline Report

• In March 2025, Karuna Therapeutics announced a phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of KarXT in male and female subjects who are aged 55 to 90 years and have mild to severe Alzheimer’s Disease (AD) with moderate to severe psychosis related to AD.
• In March 2025, BioXcel Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has closed the inspection of a single site in its TRANQUILITY II Phase 3 trial under 21 C.F.R.20.64(d)(3) and released the Establishment Inspection Report.
• DelveInsight’s Dementia Associated With Alzheimer’s Disease pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Dementia Associated With Alzheimer’s Disease treatment.
• The leading Dementia Associated With Alzheimer’s Disease Companies such as BioVie, Karuna Therapeutics, Cassava Sciences, Inc., Cognition Therapeutics, Alector, TrueBinding, KeyMed Biosciences, Alzinova, AriBio Co., Ltd., Eli Lilly & Co., AbbVie Inc., Allyx Therapeutics, Inc., Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd and others.
• Promising Dementia Associated With Alzheimer’s Disease Pipeline Therapies such as ITI-1284, Brexpiprazole, KarXT, Quetiapine Fumarate, DMB-I (Dimebon), Rifaximin SSD 40 mg IR tablet, OPC-34712, and others.

Stay informed about the cutting-edge advancements in Dementia Associated With Alzheimer’s Disease treatments. Download for updates and be a part of the revolution in care @ Dementia Associated With Alzheimer’s Disease Clinical Trials Assessment

Dementia Associated With Alzheimer’s Disease Emerging Drugs Profile

• NE3107: BioVie

NE3107 is an orally available small molecule with potential anti-inflammatory and insulin-sensitizing properties that can cross the blood-brain barrier. It was originally developed by NeurMedix and acquired by BioVie in April. The experimental molecule works by blocking the activation of two major regulators of inflammatory pathways: extracellular signal regulated kinase (ERK) and nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB). NFκB is activated by amyloid beta and tau — two proteins that form toxic clumps that contribute to Alzheimer’s — and by the pro-inflammatory molecules that it stimulates, leading to chronic inflammation. NE3107 was found to have no immunosuppressive effects and to block ERK- and NF-κB-induced inflammation without suppressing their functions involved in maintaining overall balance, such as insulin signaling and nerve cell growth and survival. Currently, the drug is in Phase III stage of development for the treatment of Alzheimer Disease.

• KarXT: Karuna Therapeutics

KarXT, a combination of xanomeline and trospium, is an investigational treatment developed by Karuna Therapeutics, primarily aimed at addressing psychosis associated with Alzheimer’s disease (AD) and schizophrenia. KarXT functions as a muscarinic receptor agonist, specifically targeting the M1 and M4 muscarinic acetylcholine receptors. Xanomeline activates these receptors, which are crucial for cognitive processes such as learning and memory. Trospium, on the other hand, is included to mitigate peripheral side effects associated with xanomeline, such as nausea and vomiting, by preventing its action on muscarinic receptors outside the brain. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Dementia Associated With Alzheimer’s Disease.

• Simufilam: Cassava Sciences

Simufilam (formerly known as PTI-125) is an investigational drug being developed by Cassava Sciences. It targets an altered form of filamin A (FLNA), a protein implicated in the disease’s pathology. Unlike traditional Alzheimer’s treatments that focus on clearing amyloid plaques, simufilam works by stabilizing FLNA, thereby potentially reducing neuroinflammation and cognitive decline associated with the disease. Currently, the drug is in the Phase III stage of development to treat Dementia Associated With Alzheimer’s Disease.

• CT-1812: Cognition Therapeutics

Cognition Therapeutics isdeveloping CT1812, an oral, brain-penetrant, small molecule therapeutic, which has been shown to protect neurons and synapses by preventing the binding of toxic oligomers. CT1812 acts as a neuroprotective agent both by shielding neurons and synapses from oligomer binding and by preventing oligomers from attaching to synapses in the first place. CT1812 may help mitigate the neurotoxic effects, slowing cognitive decline and progression of Alzheimer’s disease. Currently, the drug is in the Phase II stage of development to treat Alzheimer’s-disease.

• CM383: KeyMed Biosciences

CM383 is an investigational drug being developed for the treatment of Alzheimer’s disease. It is a small molecule designed to target the underlying mechanisms of the disease, specifically by modulating the immune response and reducing neuroinflammation, which are key factors in Alzheimer’s pathology. CM383 works by targeting the immune system’s response to amyloid-beta plaques, which are characteristic of Alzheimer’s disease. It aims to enhance the brain’s ability to clear these plaques and improve neuronal health. This approach is distinct from many traditional Alzheimer’s treatments that primarily focus on amyloid plaque reduction or cholinergic modulation. Currently, the drug is in the Phase I stage of development to treat Alzheimer’s-disease.

The Dementia Associated With Alzheimer’s Disease Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Dementia Associated With Alzheimer’s Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dementia Associated With Alzheimer’s Disease Treatment.
• Dementia Associated With Alzheimer’s Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Dementia Associated With Alzheimer’s Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dementia Associated With Alzheimer’s Disease market

Learn more about Dementia Associated With Alzheimer’s Disease Drugs opportunities in our groundbreaking Dementia Associated With Alzheimer’s Disease Research and development projects @ Dementia Associated With Alzheimer’s Disease Unmet Needs

Dementia Associated With Alzheimer’s Disease Companies

BioVie, Karuna Therapeutics, Cassava Sciences, Inc., Cognition Therapeutics, Alector, TrueBinding, KeyMed Biosciences, Alzinova, AriBio Co., Ltd., Eli Lilly & Co., AbbVie Inc., Allyx Therapeutics, Inc., Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd and others.

Dementia Associated With Alzheimer’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Dementia Associated With Alzheimer’s Disease Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Discover the latest advancements in Dementia Associated With Alzheimer’s Disease treatment by visiting our website. Stay informed about how we’re transforming the future of disease @ Dementia Associated With Alzheimer’s Disease Market Drivers and Barriers, and Future Perspectives

Scope of the Dementia Associated With Alzheimer’s Disease Pipeline Report

• Coverage- Global
• Dementia Associated With Alzheimer’s Disease Companies- BioVie, Karuna Therapeutics, Cassava Sciences, Inc., Cognition Therapeutics, Alector, TrueBinding, KeyMed Biosciences, Alzinova, AriBio Co., Ltd., Eli Lilly & Co., AbbVie Inc., Allyx Therapeutics, Inc., Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd and others.
• Dementia Associated With Alzheimer’s Disease Pipeline Therapies- ITI-1284, Brexpiprazole, KarXT, Quetiapine Fumarate, DMB-I (Dimebon), Rifaximin SSD 40 mg IR tablet, OPC-34712, and others.
• Dementia Associated With Alzheimer’s Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Dementia Associated With Alzheimer’s Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Dementia Associated With Alzheimer’s Disease Pipeline on our website @ Dementia Associated With Alzheimer’s Disease Emerging Drugs and Companies

Table of Content

1. Introduction
2. Dementia Associated With Alzheimer’s Disease Executive Summary
3. Dementia Associated With Alzheimer’s Disease Overview
4. Dementia Associated With Alzheimer’s Disease Pipeline Therapeutics
5. Dementia Associated With Alzheimer’s Disease Therapeutic Assessment
6. Dementia Associated With Alzheimer’s Disease– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. NE3107: BioVie
9. Mid Stage Products (Phase II)
10. CT-1812: Cognition Therapeutics
11. Early Stage Products (Phase I)
12. CM383: KeyMed Biosciences
13. Preclinical and Discovery Stage Products
14. Drug name: Company name
15. Inactive Products
16. Dementia Associated With Alzheimer’s Disease Key Companies
17. Dementia Associated With Alzheimer’s Disease Key Products
18. Dementia Associated With Alzheimer’s Disease- Unmet Needs
19. Dementia Associated With Alzheimer’s Disease- Market Drivers and Barriers
20. Dementia Associated With Alzheimer’s Disease- Future Perspectives and Conclusion
21. Dementia Associated With Alzheimer’s Disease Analyst Views
22. Dementia Associated With Alzheimer’s Disease Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/medical-marijuana-market-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Dementia Associated With Alzheimer’s Disease Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “Crohn’s Disease Pipeline Insight 2025” report provides comprehensive insights about 90+ companies and 90+ pipeline drugs in Crohn’s Disease pipeline landscape. It covers the Crohn’s Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Crohn’s Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Crohn’s Disease Treatment Landscape. Click here to read more @ Crohn’s Disease Pipeline Outlook

Key Takeaways from the Crohn’s Disease Pipeline Report

• In March 2025, Janssen-Cilag Ltd. announced a study to evaluate the clinical efficacy of guselkumab in fistulizing, perianal Crohn’s disease and to assess the overall safety of guselkumab.
• In March 2025, Hoffmann-La Roche conducted a phase 2, randomized, double-blind, multicenter, induction and maintenance study is designed to evaluate the safety and efficacy of RO7790121 (RVT-3101) in adult participants with moderate to severe active Crohn’s disease.
• In March 2025, AbbVie organized a study will evaluate the effectiveness and adverse events of targeted therapies (TaTs) for adult participants with moderate to severe CD.
• In January 2025:- Janssen-Cilag Ltd.:- A Phase 3, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab in Participants With Fistulizing, Perianal Crohn’s Disease. The purpose of this study to evaluate the clinical efficacy of guselkumab in fistulizing, perianal Crohn’s disease and to assess the overall safety of guselkumab.
• In January 2025:- Tr1X Inc.:- A Phase 1/2a, Open Label, Dose Escalation Study to Evaluate the Safety and Preliminary Efficacy of TRX103 in Subjects with Moderate to Severe Treatment-Refractory Crohn’s Disease. This research study is testing an investigational research product called TRX103 as a possible treatment for individuals suffering from Crohn’s Disease (CD). The primary purpose of this study is to learn how safe and effective different doses of TRX103 are when administered to individuals with CD.
• In Janssen Pharmaceutical K.K.:– A Phase 3, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Guselkumab in Participants With Moderately to Severely Active Crohn’s Disease. The purpose of this study is to evaluate the safety of Guselkumab in participants with Crohn’s disease.
• In January 2025:- AbbVie:- Crohn’s disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most frequently affecting the bowels. It can cause many different symptoms including belly pain, diarrhea, tiredness, and weight loss. Treatments are available but do not work the same for all patients or may stop working over time. This study will evaluate the effectiveness and adverse events of targeted therapies (TaTs) for adult participants with moderate to severe CD.
• DelveInsight’s Crohn’s Disease pipeline report depicts a robust space with 90+ active players working to develop 90+ pipeline therapies for Crohn’s Disease treatment.
• The leading Crohn’s Disease companies such as Janssen, RedHill Biopharma, Amgen, Pfizer, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, AbbVie, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, Priothera, SLA Pharma, HAV Vaccines Ltd, Enzo Biochem Inc., VHsquared Ltd., Stero Biotechs, Reistone Biopharma Company Limited, Qu Biologics, Provention Bio, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceuticals, Soligenix, Immunic, Atlantic Healthcare, 4D Pharma, Landos Biopharma, Protagonist Therapeutics, Roche, Eisai, Bristol-Myers Squibb, Iltoo Pharma, Fast Forward Pharmaceuticals, Suzhou Connect Biopharmaceuticals, Theravance Biopharma, TaiwanJ Pharmaceuticals, Active Biotech, Celularity, Cerecor, GlaxoSmithKline, Kang Stem Biotech, Alpha Cancer Technologies, Koutif Therapeutics, Winston Pharmaceuticals, Tract Therapeutics, Trio Medicines, Tetherex Pharmaceuticals, ChemoCentryx, Algernon Pharmaceuticals, Neuclone, Innovimmune Biotherapeutics, JHL Biotech, Intract Pharma Ltd, Innovative Pharmacological Research (IPHAR) Co Ltd, Innovation Pharmaceuticals, Exeliom Biosciences SAS, Finch Therapeutics, Akeso Biopharma, Draconis Pharma, MakScientific, Origo Biopharma, Navidea Biopharmaceuticals, Orchard Therapeutics, Xbrane, Thetis Pharmaceuticals, Temisis Therapeutics, Synedgen, Synlogic, PlantPraxis, Morphic Therapeutic, Metacrine, Curacle, Commence Bio Inc, Cloud Pharmaceuticals, Chong Kun Dang Pharmaceutical Corp, Avobis Bio LLC, Avexegen Therapeutics, Atlantic Bio Sci, Assembly Biosciences, Artelo Biosciences, Aibios Co Ltd, Aclaris Therapeutics, Athos Therapeutics, Denali Therapeutics, Educell doo and others.
• Promising Crohn’s Disease Pipeline Therapies such as Etrasimod, Infliximab, MEDI2070, Filgotinib, Risankizumab 600 mg IV, CT-P13, and others.

Discover groundbreaking developments in Crohn’s Disease therapies! Gain in-depth knowledge of key Crohn’s Disease clinical trials, emerging drugs, and market opportunities @ Crohn’s Disease Clinical Trials Assessment

Crohn’s Disease Emerging Drugs Profile

• Guselkumab: Janssen

Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation. In clinical trials, guselkumab demonstrated improved skin clearance and symptomatic improvements in dermatological manifestations of psoriasis. It is currently in Phase III of clinical trial.

• RHB-104: RedHill Biopharma

RHB-104 is a potentially groundbreaking, proprietary investigational drug in oral capsule formulation, with potent intracellular, antimycobacterial and anti-inflammatory properties. It is currently in Phase III of clinical trial.

The Crohn’s Disease Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Crohn’s Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Crohn’s Disease Treatment.
• Crohn’s Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Crohn’s Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Crohn’s Disease market

Stay informed about the Crohn’s Disease pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Crohn’s Disease Unmet Needs

Crohn’s Disease Companies

Janssen, RedHill Biopharma, Amgen, Pfizer, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Abbvie, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, Priothera, and others.

Crohn’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Crohn’s Disease Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Transform your understanding of the Crohn’s Disease Pipeline! See the latest progress in drug development and clinical research @ Crohn’s Disease Market Drivers and Barriers, and Future Perspectives

Scope of the Crohn’s Disease Pipeline Report

• Coverage- Global
• Crohn’s Disease Companies- Janssen, RedHill Biopharma, Amgen, Pfizer, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Abbvie, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, Priothera, and others.
• Crohn’s Disease Pipeline Therapies- Etrasimod, Infliximab, MEDI2070, Filgotinib, Risankizumab 600 mg IV, CT-P13, and others.
• Crohn’s Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Crohn’s Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

“Stay Ahead in Gastroenterology Research–Access the Full Crohn’s Disease Pipeline Analysis Today! @ Crohn’s Disease Drugs and Companies

Table of Content

1. Introduction
2. Crohn’s Disease Executive Summary
3. Crohn’s Disease: Overview
4. Crohn’s Disease Pipeline Therapeutics
5. Crohn’s Disease Therapeutic Assessment
6. Crohn’s Disease– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Ozanimod: Bristol-Myers Squibb
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. CBP-307: Suzhou Connect Biopharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. IMU-856: Immunic
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Crohn’s Disease Key Companies
21. Crohn’s Disease Key Products
22. Crohn’s Disease- Unmet Needs
23. Crohn’s Disease- Market Drivers and Barriers
24. Crohn’s Disease- Future Perspectives and Conclusion
25. Crohn’s Disease Analyst Views
26. Crohn’s Disease Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/medical-marijuana-market-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Crohn’s Disease Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “Chronic Kidney Disease Pipeline Insight 2025” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in the Chronic Kidney Disease pipeline landscape. It covers the Chronic Kidney Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Kidney Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Chronic Kidney Disease Research. Learn more about our innovative pipeline today! @ Chronic Kidney Disease Pipeline Outlook

Key Takeaways from the Chronic Kidney Disease Pipeline Report

• In March 2025, Novo Nordisk A/S announced a study evaluates the safety of different doses of a new medicine called NNC0519 0130. It also looks into how the medicine may improve kidney function in participants with chronic kidney disease with or without type 2 diabetes, living with overweight or obesity. The participants will either get NNC0519-0130 (a new medicine), semaglutide (a medicine that doctors can already prescribe), or placebo (a “dummy” substance). Which treatment the participant will get is decided by chance. The study will last for up to 43 weeks.
• In March 2025, Bayer organized a phase 2b Dose-finding, Randomized, Placebo-controlled, Double-blind Study to Evaluate Efficacy and Safety of BAY 3283142 on Top of Standard of Care in Reducing Albuminuria in Patients With Chronic Kidney Disease.
• In March 2025, Shandong Suncadia Medicine Co., Ltd. conducted a phase II Clinical Study of Efficacy and Safety of HRS-1780 Tablets and Henagliflozin Proline Tablets in the Treatment of Patients With Chronic Kidney Disease (Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Design).
• In March 2025, Boehringer Ingelheim conducted this study is open to adults with chronic kidney disease at risk of progression. People with and without type 2 diabetes can take part in this study. The study is open to people who take other medicines called angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB). People who already take empagliflozin or any other sodium-glucose cotransporter-2 inhibitor (SGLT2i) can also join. The study is also open to people who currently do not take any of these treatments. The purpose of this study is to find out whether a medicine called BI 690517 helps people with chronic kidney disease when taken in combination with a study medicine called empagliflozin. Worsening of kidney function increases the risk for kidney failure, cardiovascular disease, and heart disease.
• In March 2025, Novartis Pharmaceuticals announced the ASSIST study is a phase 2, double-blind, placebo-controlled crossover study to evaluate the safety and efficacy of atrasentan vs. placebo in subjects with IgA nephropathy (IgAN) while on background standard of care therapy and an SGLT2 inhibitor (SGLT2i).
• DelveInsight’s Chronic Kidney Disease pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Chronic Kidney Disease treatment.
• The leading Chronic Kidney Disease Companies such as AstraZeneca, Eli Lilly and Company, Shandong Suncadia Medicine, Boehringer Ingelheim, AdAlta, Alebund Pharmaceuticals, SCOHIA PHARMA, DiaMedica Therapeutics, Roche, MC2 Therapeutics, Allena Pharmaceuticals, Regulus Therapeutics, UnicoCell Biomed, Regeneron Pharmaceuticals and others.
• Promising Chronic Kidney Disease Pipeline Therapies such as roxadustat, Monofer®, AZD5718, Dapagliflozin 10 mg, MEDI8367, AST-120, and others.

Stay informed about the cutting-edge advancements in Chronic Kidney Disease treatments. Download for updates and be a part of the revolution in care @ Chronic Kidney Disease Clinical Trials Assessment

Chronic Kidney Disease Emerging Drugs Profile

• Baxdrostat : AstraZeneca

Baxdrostat, a highly potent inhibitor of aldosterone synthase, exhibits greater selectivity for aldosterone synthase compared to existing ASIs. Initial studies in cynomolgus monkeys demonstrated its ability to decrease aldosterone production, prompting further investigation in humans. The mechanism of action of baxdrostat involves inhibiting the enzyme aldosterone synthase, which is responsible for the final step in aldosterone biosynthesis. By selectively blocking this enzyme, baxdrostat reduces aldosterone levels, leading to decreased sodium reabsorption and fluid retention, ultimately lowering blood pressure. The drug is currently being evaluated in the Phase III stage of development for the treatment of patients with CKD.

• Ziltivekimab: Novo Nordisk

Ziltivekimab is a proprietary anti-interleukin-6 ligand monoclonal antibody (anti-IL6 mAb), targeting residual inflammatory cardiovascular risk in patients living with advanced chronic kidney disease (CKD). Ziltivekimab is being developed a therapy intended to reduce the risk of major cardiovascular adverse events in chronic kidney disease (CKD) patients with atherosclerotic cardiovascular disease (ASCVD) and inflammation. Patients who are diagnosed with moderate to severe CKD and have ASCVD and inflammation are at risk for an adverse cardiovascular event at a high rate and there are no approved therapies to prevent this risk. The proinflammatory cytokine, interleukin-6 (IL-6) has been shown to be an independent, causal factor of ASCVD with evidence generated from human genetic studies and preclinical studies. The drug is being evaluated in the Phase III stage of development to treat patients with moderate to severe chronic kidney disease.

• BI-685509: Boehringer Ingelheim

BI 685509 is a novel small soluble guanylate cyclase (sGC) molecule activator that exhibits an in vitro profile consistent with that of an sGC activator. BI 685509 reduced proteinuria and glomerulosclerosis in the ZSF1 rat, a model of diabetic kidney disease (DKD), and reduced tubulointerstitial fibrosis in a 7-day unilateral ureteral obstruction model in rats. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Chronic Kidney Disease.

• PXL770: Poxel SA

PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). Currently, the drug is in the Phase I stage of Clinical trial evaluation for the treatment of Autosomal Dominant Polycystic Kidney Disease.

• RGLS8429: Regulus Therapeutics

RGLS8429 is a novel, next-generation oligonucleotide for the treatment of ADPKD designed to inhibit miR-17 and to preferentially target the kidney. Administration of RGLS8429 has shown robust data in preclinical models, where clear improvements in kidney function, size, and other measures of disease severity have been demonstrated along with a superior pharmacologic profile in preclinical studies compared to Regulus’ first-generation compound. Currently, the drug is in Phase I for the treatment of Chronic Kidney Disease.

The Chronic Kidney Disease Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Kidney Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Kidney Disease Treatment.
• Chronic Kidney Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Chronic Kidney Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Kidney Disease market

Learn more about Chronic Kidney Disease Drugs opportunities in our groundbreaking Chronic Kidney Disease Research and development projects @ Chronic Kidney Disease Unmet Needs

Chronic Kidney Disease Companies

AstraZeneca, Eli Lilly and Company, Shandong Suncadia Medicine, Boehringer Ingelheim, AdAlta, Alebund Pharmaceuticals, SCOHIA PHARMA, DiaMedica Therapeutics, Roche, MC2 Therapeutics, Allena Pharmaceuticals, Regulus Therapeutics, UnicoCell Biomed, Regeneron Pharmaceuticals and others.

Chronic Kidney Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Chronic Kidney Disease Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Discover the latest advancements in Chronic Kidney Disease treatment by visiting our website. Stay informed about how we’re transforming the future of disease @ Chronic Kidney Disease Market Drivers and Barriers, and Future Perspectives

Scope of the Chronic Kidney Disease Pipeline Report

• Coverage- Global
• Chronic Kidney Disease Companies- AstraZeneca, Eli Lilly and Company, Shandong Suncadia Medicine, Boehringer Ingelheim, AdAlta, Alebund Pharmaceuticals, SCOHIA PHARMA, DiaMedica Therapeutics, Roche, MC2 Therapeutics, Allena Pharmaceuticals, Regulus Therapeutics, UnicoCell Biomed, Regeneron Pharmaceuticals and others.
• Chronic Kidney Disease Pipeline Therapies- Roxadustat, Monofer®, AZD5718, Dapagliflozin 10 mg, MEDI8367, AST-120, and others.
• Chronic Kidney Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Chronic Kidney Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Chronic Kidney Disease Pipeline on our website @ Chronic Kidney Disease Emerging Drugs and Companies

Table of Content

1. Introduction
2. Executive Summary
3. Chronic Kidney Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Chronic Kidney Disease– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Baxdrostat : AstraZeneca
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. BI-685509: Boehringer Ingelheim
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. RGLS8429: Regulus Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Chronic Kidney Disease Key Companies
21. Chronic Kidney Disease Key Products
22. Chronic Kidney Disease- Unmet Needs
23. Chronic Kidney Disease- Market Drivers and Barriers
24. Chronic Kidney Disease- Future Perspectives and Conclusion
25. Chronic Kidney Disease Analyst Views
26. Chronic Kidney Disease Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/medical-marijuana-market-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Kidney Disease Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “Colorectal Cancer Pipeline Insight 2025” report provides comprehensive insights about 195+ companies and 200+ pipeline drugs in Colorectal Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Colorectal Cancer Research. Learn more about our innovative pipeline today! @ Colorectal Cancer Pipeline Outlook

Key Takeaways from the Colorectal Cancer Pipeline Report

• In March 2025, HiberCell, Inc. announced a study of phase 1b, safety, pharmacokinetic, and efficacy, multicenter, dose-escalating Study of Imprime PGG™ Injection dosed in combination with Cetuximab and concomitant irinotecan therapy. Enrolled patients will have a confirmed diagnosis of recurrent or progressive colorectal carcinoma following treatment with a 5-fluorouracil-containing regimen.
• In March 2025, Bristol-Myers Squibb organized a study is to investigate treatment with nivolumab in combination with trametinib with or without ipilimumab in participants with previously treated cancer of the colon or rectum that has spread.
• In March 2025, Seagen conducted a study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease.
• In March 2025, Janssen Research & Development, LLC announced a study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus either cetuximab or bevacizumab and FOLFIRI given to participants with Kirsten rat sarcoma viral oncogene/ neuroblastoma RAS viral oncogene homolog (KRAS/ NRAS) and v-raf murine sarcoma viral oncogene homolog B (BRAF) wild-type recurrent, unresectable or metastatic colorectal cancer who have previously received chemotherapy.
• DelveInsight’s Colorectal Cancer pipeline report depicts a robust space with 195+ active players working to develop 200+ pipeline therapies for Acute Lymphocytic Leukemia treatment.
• The leading Colorectal Cancer Companies such as Exelixis, Mirati Therapeutics, Merck Sharp & Dohme LLC, Daiichi Sankyo Company, Inspirna, Lyell Immunopharma, Genentech, Cantargia AB, Arcus Biosciences, Inc., Neogap Therapeutics AB, Criterium, Inc., Daiichi Sankyo, Inc., Bristol-Myers Squibb, Celyad Oncology SA, Pfizer, Akeso, Menarini Group, Elpiscience (Suzhou) Biopharma, Ltd., BeyondBio Inc., Shanghai Henlius Biotech, Rottapharm Biotech, Innovative Cellular Therapeutics Inc., BioNTech SE, and others.
• Promising Colorectal Cancer Therapies such as Patritumab Deruxtecan, Adagrasib, Geptanolimab, PolyPEPI1018, Grapiprant, eFT508, MEN1611, Aldoxorubicin Hydrochloride, Etrumadenant, AL2846, ABI-009, RO7198457, Dabrafenib, AlloStim, TG6002, Onvansertib, BLYG8824A, Napabucasin, GM102, QL1203, CPGJ602, PM060184, Donafenib, IBI310, Spartalizumab, CMAB009, YYB101, ATP128, Vicriviroc, CXD101, Arfolitixorin, SGM-101, RRx-001, APR003, E7386, Trastuzumab, Trilaciclib, MGN1703, BBI608, CYAD-101, SHR-A1811, EDP1503, SCT-I10A, KL-140, V941, NKTR-255, TEW-7197, MGD019, KPT-8602, GRT-C901, LUM015, IDE196, CAN04, NC410, LOAd703, CEA CAR-T cells, BOLD-100, OBI-833, GRT-C903, IGM-8444, RGX-202-01, NE-201, DS-8201, GCC19CART, M 9140, LYL845, and others.

Stay informed about the cutting-edge advancements in Colorectal Cancer treatments. Download for updates and be a part of the revolution in care @ Colorectal Cancer Clinical Trials Assessment

Colorectal Cancer Emerging Drugs Profile

• XL092 : Exelixis

XL092 is an investigational small molecule, oral tyrosine kinase inhibitors (TKI) that inhibits the activity of receptor tyrosine kinases involved in cancer growth and spread, including VEGF receptors, MET, AXL and MER. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes like oncogenesis, metastasis, and tumor angiogenesis. Currently it is in Phase III stage of clinical trial evaluation to treat Colorectal Cancer.

• Adagrasb : Mirati Therapeutics

Adagrasib is an investigational, highly selective, and potent oral small-molecule inhibitor of KRASG12C that is optimized to sustain target inhibition, an attribute that could be important to treat KRASG12C-mutated cancers. The drug candidate is being evaluated as monotherapy and in combination with other anti-cancer therapies in patients with advanced KRASG12C-mutated colorectal cancer. Currently being evaluated in the Phase III studies.

• Olaparib : Merck Sharp & Dohme LLC/Astrazeneca

Olaparib is an investigational is a first-in-class Poly (ADP-ribose) polymerase PARP inhibitors and the first targeted treatment that potentially exploit DNA damage response (DDR) pathway deficiencies, like BRCA mutations, to preferentially kill cancer cells. Olaparib is being jointly developed and commercialized by AstraZeneca and Merck. Currently the drug is being evaluated in Phase III for the treatment of Colorectal Cancer.

• DS-8201: Daiichi Sankyo

DS-8201 a proprietary antibody-drug conjugate (ADC) is a smart chemotherapy comprised of a humanized HER2 antibody attached to a novel topoisomerase I inhibitor payload by a tetra peptide-based linker. It is designed to target and deliver chemotherapy inside cancer cells and reduce systemic exposure to the cytotoxic payload (or chemotherapy) compared to the way chemotherapy is commonly delivered. The drug is been developed in collaboration with AstraZeneca. The drug is in Phase II stage of clinical trials.

• Ompenaclid: Inspirna

Ompenaclid is a first in class oral small molecule inhibitor of the creatine transport channel SLC6A8 a novel target that is enriched under hypoxic conditions and provides tumor cells with an additional energy source. Ompenaclid triggers tumor regressions in CRC patients by inducing apoptosis of tumor cells. It is based on Rgenix technology. The drug is in Phase II stage of clinical trials.

• LYL845: Lyell Immunopharma

LYL845, an autologous tumor-infiltrating lymphocytes (TIL). It is administered through the intravenous route. It is being developed based on an ex vivo epigenetic reprogramming (Epi-R) technology platform is currently being investigated in a Phase 1 clinical trial in patients suffering with relapsed or refractory metastatic colorectal cancer.

• RG6286: Genentech

RG6286 (BLYG-8824A) is under development for the treatment of relapsed or refractory, advanced, or metastatic colorectal cancer. It is new chemical entity, administered through an intravenous route currently being investigated in a Phase 1 clinical trial.

The Colorectal Cancer Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Colorectal Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Colorectal Cancer Treatment.
• Colorectal Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Colorectal Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Colorectal Cancer market

Learn more about Colorectal Cancer Drugs opportunities in our groundbreaking Colorectal Cancer Research and development projects @ Colorectal Cancer Unmet Needs

Colorectal Cancer Companies

Exelixis, Mirati Therapeutics, Merck Sharp & Dohme LLC, Daiichi Sankyo Company, Inspirna, Lyell Immunopharma, Genentech, Cantargia AB, Arcus Biosciences, Inc., Neogap Therapeutics AB, Criterium, Inc., Daiichi Sankyo, Inc., Bristol-Myers Squibb, Celyad Oncology SA, Pfizer, Akeso, Menarini Group, Elpiscience (Suzhou) Biopharma, Ltd., BeyondBio Inc., Shanghai Henlius Biotech, Rottapharm Biotech, Innovative Cellular Therapeutics Inc., BioNTech SE and others.

Colorectal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Colorectal Cancer Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Discover the latest advancements in Colorectal Cancer treatment by visiting our website. Stay informed about how we’re transforming the future of disease @ Colorectal Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the Colorectal Cancer Pipeline Report

• Coverage- Global
• Colorectal Cancer Companies- Exelixis, Mirati Therapeutics, Merck Sharp & Dohme LLC, Daiichi Sankyo Company, Inspirna, Lyell Immunopharma, Genentech, Cantargia AB, Arcus Biosciences, Inc., Neogap Therapeutics AB, Criterium, Inc., Daiichi Sankyo, Inc., Bristol-Myers Squibb, Celyad Oncology SA, Pfizer, Akeso, Menarini Group, Elpiscience (Suzhou) Biopharma, Ltd., BeyondBio Inc., Shanghai Henlius Biotech, Rottapharm Biotech, Innovative Cellular Therapeutics Inc., BioNTech SE, and others.
• Colorectal Cancer Therapies- Patritumab Deruxtecan, Adagrasib, Geptanolimab, PolyPEPI1018, Grapiprant, eFT508, MEN1611, Aldoxorubicin Hydrochloride, Etrumadenant, AL2846, ABI-009, RO7198457, Dabrafenib, AlloStim, TG6002, Onvansertib, BLYG8824A, Napabucasin, GM102, QL1203, CPGJ602, PM060184, Donafenib, IBI310, Spartalizumab, CMAB009, YYB101, ATP128, Vicriviroc, CXD101, Arfolitixorin, SGM-101, RRx-001, APR003, E7386, Trastuzumab, Trilaciclib, MGN1703, BBI608, CYAD-101, SHR-A1811, EDP1503, SCT-I10A, KL-140, V941, NKTR-255, TEW-7197, MGD019, KPT-8602, GRT-C901, LUM015, IDE196, CAN04, NC410, LOAd703, CEA CAR-T cells, BOLD-100, OBI-833, GRT-C903, IGM-8444, RGX-202-01, NE-201, DS-8201, GCC19CART, M 9140, LYL845, and others.
• Colorectal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Colorectal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Colorectal Cancer Pipeline on our website @ Colorectal Cancer Emerging Drugs and Companies

Table of Content

1. Introduction
2. Executive Summary
3. Colorectal Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Comparative Analysis
8. XL092: Exelixis
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Early Stage Products (Phase I)
12. LYL845: Lyell Immunopharma
13. Inactive Products
14. Colorectal Cancer Key Companies
15. Colorectal Cancer Key Products
16. Colorectal Cancer – Unmet Needs
17. Colorectal Cancer – Market Drivers and Barriers
18. Colorectal Cancer – Future Perspectives and Conclusion
19. Colorectal Cancer Analyst Views
20. Colorectal Cancer Key Companies
21. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/medical-marijuana-market-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Colorectal Cancer Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “Acute Lymphocytic Leukemia Pipeline Insight 2025” report provides comprehensive insights about 125+ companies and 130+ pipeline drugs in Acute Lymphocytic Leukemia pipeline landscape. It covers the Acute Lymphocytic Leukemia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Acute Lymphocytic Leukemia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Acute Lymphocytic Leukemia Research. Learn more about our innovative pipeline today! @ Acute Lymphocytic Leukemia Pipeline Outlook

Key Takeaways from the Acute Lymphocytic Leukemia Pipeline Report

• In March 2025, Janssen Research & Development, LLC conducted a study is to evaluate the efficacy of daratumumab in addition to standard chemotherapy in pediatric participants with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LL) and T-cell ALL/LL as measured by the complete response (CR) rate.
• In March 2025, Pfizer organized a phase 2 study is designed to evaluate the superiority of InO monotherapy vs ALLR3 after 1 cycle of induction treatment in paediatric participants (between 1 and
• In March 2025, Amgen announced a phase 2 Study to Evaluate Efficacy, Safety, and Pharmacokinetics (PK) of Blinatumomab in Chinese Pediatric Subjects With Relapsed or Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL).
• In March 2025, AbbVie organized an extension study is to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefit from receiving venetoclax in ongoing studies.
• DelveInsight’s Acute Lymphocytic Leukemia pipeline report depicts a robust space with 125+ active players working to develop 130+ pipeline therapies for Acute Lymphocytic Leukemia treatment.
• The leading Acute Lymphocytic Leukemia Companies such as Orca Biosystems, Inc, Jazz Pharmaceuticals, Shenzhen TargetRx, Inc, Cellectis, ADC Therapeutics S.A., Kunming Hope of Health Hospital, Beam Therapeutics Inc., Shenzhen BinDeBio Ltd., Kite, A Gilead Company, Sumitomo Pharma America, Inc., In8bio Inc., Fate Therapeutics, Sichuan Baili Pharmaceutical Co., Ltd., Janssen Research & Development, LLC, Medolution Ltd., Kymera Therapeutics, Inc., Kite, A Gilead Company | Gilead Sciences, Newave Pharmaceutical Inc, Servier, Meryx, Inc., Armaceutica, Inc., Hangzhou Qihan Biotech Co., Ltd., Nanjing Bioheng Biotech, Sanofi, Syndax Pharmaceuticals, Vincerx Pharma, Inc. and others.
• Promising Acute Lymphocytic Leukemia Pipeline Therapies such as Omitted Doxorubicin, Blinatumomab, Dexamethasone, Vincrisitne, Recombinant Asparaginase, Inotuzumab Ozogamicin and others.

Stay informed about the cutting-edge advancements in Acute Lymphocytic Leukemia treatments. Download for updates and be a part of the revolution in care @ Acute Lymphocytic Leukemia Clinical Trials Assessment

Acute Lymphocytic Leukemia Emerging Drugs Profile

• Orca-T: Orca Biosystems, Inc.

Orca-T is an investigational high-precision cell therapy designed to replace a patient’s cancerous blood and immune system with a healthy one while dramatically lowering their risk of developing GvHD and other potentially life-threatening side effects. In the Phase Ib/II study, when measured against a concurrent, nonrandomized single-center comparator for allogeneic transplant patients, Orca-T demonstrated preliminary evidence of significantly higher GvHD-free, relapse-free survival rates after 1 year, improved relapse-free survival rates and lower rates of chronic GvHD. Currently, the drug is in Phase III stage of its development for the treatment of ALL.

• TGRX-814: Shenzhen TargetRx, Inc.

TGRX-814 is a highly selective inhibitor of the BCL2 (over BCL-XL) for the treatment of CLL with or without the del(17p)/TP53 mutation, NHL, SLL, DLBL, MM, etc. Notably, TGRX-814 has an excellent selectivity profile for BCL-XL. TGRX-814 is modified and optimized through classical bioisosterism and molecule simulation technologies. In-vitro and in-vivo assays have shown that TGRX-814 improves oral metabolism, increases in vivo exposure, and reduces compound clearance while maintaining in vitro and in vivo bioactivity. Moreover, TGRX-814 obtained over 2-fold increase in bioavailability compared to the marketed drug Venetoclax, resulting in a significant increase in efficacy. Currently, the drug is in Phase I/II stage of its development for the treatment of ALL.

• UCART22: Cellectis

UCART22 is one of Cellectis’ wholly owned, allogeneic, off-the-shelf gene-edited T-cell product candidates designed for the treatment of relapsed and refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). Like CD19, CD22 is a cell surface antigen expressed from the pre-B-cell stage of development through mature B-cells. CD22 expression occurs in more than 90% of patients with B-ALL. It is currently in phase I stage of development. Currently, the drug is in Phase I stage of its development for the treatment of ALL.

The Acute Lymphocytic Leukemia Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Acute Lymphocytic Leukemia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Lymphocytic Leukemia Treatment.
• Acute Lymphocytic Leukemia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Acute Lymphocytic Leukemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute Lymphocytic Leukemia market

Learn more about Acute Lymphocytic Leukemia Drugs opportunities in our groundbreaking Colo Acute Lymphocytic Leukemia Research and development projects @ Acute Lymphocytic Leukemia Unmet Needs

Acute Lymphocytic Leukemia Companies

Orca Biosystems, Inc, Jazz Pharmaceuticals, Shenzhen TargetRx, Inc, Cellectis, ADC Therapeutics S.A., Kunming Hope of Health Hospital, Beam Therapeutics Inc., Shenzhen BinDeBio Ltd., Kite, A Gilead Company, Sumitomo Pharma America, Inc., In8bio Inc., Fate Therapeutics, Sichuan Baili Pharmaceutical Co., Ltd., Janssen Research & Development, LLC, Medolution Ltd., Kymera Therapeutics, Inc., Kite, A Gilead Company | Gilead Sciences, Newave Pharmaceutical Inc, Servier, Meryx, Inc., Armaceutica, Inc., Hangzhou Qihan Biotech Co., Ltd., Nanjing Bioheng Biotech, Sanofi, Syndax Pharmaceuticals, Vincerx Pharma, Inc. and others.

Acute Lymphocytic Leukemia (ALL) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Acute Lymphocytic Leukemia Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Discover the latest advancements in Acute Lymphocytic Leukemia Treatment by visiting our website. Stay informed about how we’re transforming the future of disease @ Acute Lymphocytic Leukemia Market Drivers and Barriers, and Future Perspectives

Scope of the Acute Lymphocytic Leukemia Pipeline Report

• Coverage- Global
• Acute Lymphocytic Leukemia Companies- Orca Biosystems, Inc, Jazz Pharmaceuticals, Shenzhen TargetRx, Inc, Cellectis, ADC Therapeutics S.A., Kunming Hope of Health Hospital, Beam Therapeutics Inc., Shenzhen BinDeBio Ltd., Kite, A Gilead Company, Sumitomo Pharma America, Inc., In8bio Inc., Fate Therapeutics, Sichuan Baili Pharmaceutical Co., Ltd., Janssen Research & Development, LLC, Medolution Ltd., Kymera Therapeutics, Inc., Kite, A Gilead Company | Gilead Sciences, Newave Pharmaceutical Inc, Servier, Meryx, Inc., Armaceutica, Inc., Hangzhou Qihan Biotech Co., Ltd., Nanjing Bioheng Biotech, Sanofi, Syndax Pharmaceuticals, Vincerx Pharma, Inc. and others.
• Acute Lymphocytic Leukemia Pipeline Therapies- Omitted Doxorubicin, Blinatumomab, Dexamethasone, Vincrisitne, Recombinant Asparaginase, Inotuzumab Ozogamicin and others.
• Acute Lymphocytic Leukemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Acute Lymphocytic Leukemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Acute Lymphocytic Leukemia Pipeline on our website @ Acute Lymphocytic Leukemia Emerging Drugs and Companies

Table of Content

1. Introduction
2. Executive Summary
3. Acute-Lymphocytic-Leukemia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Acute-Lymphocytic-Leukemia– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Orca-T: Orca Biosystems, Inc.
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Product Name: Company Name
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. TGRX-814: Shenzhen TargetRx, Inc.
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Acute-Lymphocytic-Leukemia Key Companies
21. Acute-Lymphocytic-Leukemia Key Products
22. Acute-Lymphocytic-Leukemia- Unmet Needs
23. Acute-Lymphocytic-Leukemia- Market Drivers and Barriers
24. Acute-Lymphocytic-Leukemia- Future Perspectives and Conclusion
25. Acute-Lymphocytic-Leukemia Analyst Views
26. Acute-Lymphocytic-Leukemia Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/medical-marijuana-market-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Acute Lymphocytic Leukemia Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies